Shares of BigBear.ai Slide as Defense AI Hype Wavers

McLean, Virginia, May 15, 2026, 15:04 EDT

BigBear.ai shares slipped roughly 5% to $4.16 Friday afternoon.
First-quarter backlog climbed 14% to $281.9 million, driven in part by a $53 million classified contract.
BigBear.ai’s revenue held steady at $34.4 million, and the company maintained its 2026 sales outlook of $135 million to $165 million.

BigBear.ai Holdings Inc. slid roughly 5% Friday afternoon, with shares sitting at $4.16 by 3:00 p.m. EDT as the market remained open. Investors took a hard look at the defense-AI firm’s expanding backlog, but stagnant revenue and another loss for the quarter kept pressure on the stock.

BigBear.ai is suddenly in the spotlight, serving as a gauge for a more focused AI bet—not semis, not chatbot startups, but software landing with defense, intelligence, and security clients across borders and travel. Buyers seem interested. Investors, for their part, keep pressing for proof: how quickly do those contract signings actually show up in the top line?

BigBear.ai posted Q1 revenue of $34.4 million, slipping 1% from $34.8 million a year ago. The dip came as Army program volumes fell, though that was cushioned in part by contributions from Ask Sage, the generative AI platform BigBear.ai picked up late last year.

Backlog jumped 14% from the fourth quarter, hitting $281.9 million. According to BigBear.ai, most of that growth can be traced to a $53 million sole-source classified prime contract—essentially, an award made straight to a single contractor, bypassing the usual competitive process.

Chief Executive Kevin McAleenan credited first-quarter gains of almost $75 million with keeping the company’s 2026 revenue plan intact. Chief Financial Officer Sean Ricker cited “strong gross margin expansion” tied to generative AI revenue, according to the earnings release. SEC

Results were a mixed bag. Gross margin jumped to 34.0%, up from 21.3% in the same period last year. But adjusted EBITDA loss deepened, coming in at $9.9 million versus a $7.0 million loss. Net loss shrank to $56.8 million from $62.0 million.

Ask Sage sits at the heart of this. According to a filing, Ask Sage brought in roughly $6.1 million in revenue for the quarter, posting a net loss of about $551,000. BigBear.ai pointed to the platform’s role in moving the business toward more profitable generative AI offerings.

BigBear.ai is working to carve out space among heavyweight government-AI players. This week, Reuters highlighted Ukraine’s deepening partnership with Palantir Technologies, tapping the firm for battlefield data analysis and drone defense solutions. C3 AI, meanwhile, continues to push its own defense and government-facing AI for decision-making and operational support.

The risk is clear enough: backlog doesn’t guarantee money in hand. In its latest quarterly filing, BigBear.ai notes that a large chunk of previous revenue has come from federal government contracts—many only partially funded at the time of award. On top of that, contracts with customers like the federal government can be canceled for convenience. The company’s own warning: backlog might not convert to revenue this period—or ever.

BigBear.ai’s latest numbers show management isn’t boxed in. As of March 31, the company held $431.5 million in cash and investments. It’s wiped out the last $124.6 million of its 2029 convertible notes, and now just $16.5 million in 2026 notes remain, due to be settled before the year wraps up.

BigBear.ai isn’t getting the kind of boost some AI plays have seen. Investors still seem to see it mainly as a government contractor, not a breakout tech story. The company stuck with its revenue outlook for the year, holding guidance at $135 million to $165 million. Now, attention turns to whether classified projects, travel-security deals, and the Ask Sage platform can help steady that revenue stream.

Khadija Saeed Latest posts

A dedicated markets reporter, she covers stocks, macroeconomics, and major business developments with a sharp eye for detail and accuracy.

View all

Treasury Yields Surge as Bond Sell-Off Hits Markets; U.S. 30-Year Treasury Hits 2007 High
May 15, 2026, 3:47 PM EDT. Treasury yields soared amid a broad bond sell-off, pushing the U.S. 30-year Treasury yield to its highest level since 2007. Rising yields, which move inversely to bond prices, reflect investor concerns about inflation and potential Federal Reserve interest rate hikes. The surge rattled fixed income markets, signaling pressure on borrowing costs and impacting various asset classes globally. Market participants closely watch these moves as they provide insight into economic outlook and monetary policy expectations.

AT&T, Verizon, T-Mobile Rally Against Dead Zones With Uncommon Satellite Move, Eye Starlink Push

15 May 2026

AT&T, Verizon, and T-Mobile announced plans to jointly build a satellite-based network to eliminate U.S. wireless dead zones, aiming to connect ordinary phones directly to satellites. The move follows the FCC’s approval of EchoStar’s $40 billion spectrum sale to SpaceX and AT&T. The carriers have an agreement in principle but have not finalized terms. AT&T reported $31.5 billion in Q1 revenue and $126.4 billion in net debt.

Ambev Stock Faces Reality Check After Brazil Beer Boom and UBS Sell Call

15 May 2026

Ambev’s São Paulo shares fell 0.25% to 15.73 reais Friday, despite UBS raising its target price but maintaining a Sell rating. First-quarter profit rose 2.1% to 3.89 billion reais, with Brazil Beer volumes hitting a record and net revenue up 9.6%. Cash flow surged 162.5% to 3.16 billion reais. Consolidated cash cost of goods sold per hectoliter climbed 8.5%.

Pfizer Inc Looks to India for Growth—But Proof Remains Elusive for Investors

15 May 2026

Pfizer is increasing investment in India for cancer drugs, obesity treatments, and vaccines as it seeks growth beyond COVID-era sales. The company reported Q1 revenue of $14.5 billion, up 5%, but expects a $1.5 billion hit this year from generic competition. Shares fell 1.8% to $25.29 in New York trading. In Europe, Pfizer won expanded approval for its hemophilia drug Hympavzi.